RESUMEN
BACKGROUND: Treatment of acute pain in older patients is a common challenge faced in emergency departments (EDs). Despite many studies that have investigated chronic analgesic use in the elderly, data on patterns of acute use, especially in EDs, of analgesics according to patient characteristics is scarce. OBJECTIVE: To investigate sex- and age-related patterns of analgesic use in the Spanish EDs and determine differences in age-related patterns according to patient sex. DESIGN: A secondary analysis of the Emergency Department and Elderly Needs (EDEN) multipurpose cohort. SETTING: Fifty-two Spanish EDs (17% of Spanish EDs covering 25% of Spanish population). PARTICIPANTS: All patients' ≥65 years attending ED during 1 week (April 1-7, 2019). Patient characteristics recorded included age, sex, chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and opiates, comorbidity, dependence, dementia, depression, ability to walk and previous falls. Analgesics used in the ED were categorized in three groups: non-NSAID non-opioids (mainly paracetamol and metamizole, PM), NSAIDs, and opiates. OUTCOME MEASURES: Frequency of analgesic use was quantified, and the relationship between sex and age and analgesic use (in general and for each analgesic group) was assessed by unadjusted and adjusted logistic regression and restricted cubic spline models. Interaction between sex and age was explored. MAIN RESULTS: We included 24â 573 patients, and 6678 (27.2%) received analgesics in the ED: 5551 (22.6%) PM, 1661 (6.8%) NSAIDs and 937 (3.8%) opiates (1312 received combinations). Analgesics were more frequently used in women (adjusted ORâ =â 1.076, 95%CIâ =â 1.014-1.142), as well as with NSAID (1.205, 1.083-1.341). Analgesic use increased with age, increasing PM and decreasing NSAIDs use. Opiate use remained quite constant across age and sex. Interaction of sex with age was present for the use of analgesics in general ( P â =â 0.006), for PM ( P â <â 0.001) and for opiates ( P â =â 0.033), with higher use of all these analgesics in women. CONCLUSION: Use of analgesics in older individuals in EDs is mildly augmented in women and increases with age, with PM use increasing and NSAIDs decreasing with age. Conversely, opiate use is quite constant according to sex and age. Age-related patterns differ according to sex, with age-related curves of women showing higher probabilities than those of men to receive any analgesic, PM or opiates.
Asunto(s)
Analgésicos , Alcaloides Opiáceos , Masculino , Humanos , Femenino , Anciano , Analgésicos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Acetaminofén/uso terapéutico , Servicio de Urgencia en Hospital , Analgésicos Opioides/uso terapéuticoRESUMEN
INTRODUCTION: Mortality in emergency departments (EDs) is not well known. This study aimed to assess the impact of the first-wave pandemic on deaths accounted in the ED of older patients with COVID and non-COVID diseases. METHODS: We used data from the Emergency Department and Elderly Needs (EDEN) cohort (pre-COVID period) and from the EDEN-COVID cohort (COVID period) that included all patients ≥65 years seen in 52 Spanish EDs from April 1 to 7, 2019, and March 30 to April 5, 2020, respectively. We recorded patient characteristics and final destination at ED. We compared older patients in the pre-COVID period, with older patients with non-COVID and with COVID-19. ED-mortality (before discharge or hospitalization) is the prior outcome and is expressed as an adjusted odds ratio (aOR) with 95% interval confidence. RESULTS: We included 23,338 older patients from the pre-COVID period (aged 78.3 [8.1] years), 6,715 patients with non-COVID conditions (aged 78.9 [8.2] years) and 3,055 with COVID (aged 78.3 [8.3] years) from the COVID period. Compared to the older patients, pre-COVID period, patients with non-COVID and with COVID-19 were more often male, referred by a doctor and by ambulance, with more comorbidity and disability, dementia, nursing home, and more risk according to qSOFA, respectively (p < 0.001). Compared to the pre-COVID period, patients with non-COVID and with COVID-19 were more often to be hospitalized from ED (24.8% vs. 44.3% vs. 79.1%) and were more often to die in ED (0.6% vs. 1.2% vs. 2.2%), respectively (p < 0.001). Compared to the pre-COVID period, aOR for age, sex, comorbidity and disability, ED mortality in elderly patients cared in ED during the COVID period was 2.31 (95% confidence interval [CI]: 1.76-3.06), and 3.75 (95% CI: 2.77-5.07) for patients with COVID. By adding the variable qSOFA to the model, such OR were 1.59 (95% CI: 1.11-2.30) and 2.16 (95% CI: 1.47-3.17), respectively. CONCLUSIONS: During the early first pandemic wave of COVID-19, more complex and life-threatening older with COVID and non-COVID diseases were seen compared to the pre-COVID period. In addition, the need for hospitalization and the ED mortality doubled in non-COVID and tripled in COVID diagnosis. This increase in ED mortality is not only explained by the complexity or severity of the elderly patients but also because of the system's overload.
Asunto(s)
COVID-19 , Pandemias , Anciano , Humanos , Masculino , COVID-19/epidemiología , Estudios Retrospectivos , Hospitalización , Servicio de Urgencia en HospitalRESUMEN
Fibromyalgia syndrome (FMS) is a chronic widespread pain syndrome that is accompanied by fatigue, sleep disturbances, anxiety, depression, lack of concentration, and neurocognitive impairment. As the currently available drugs are not completely successful against these symptoms and frequently have several side effects, many scientists have taken on the task of looking for nonpharmacological remedies. Many of the FMS-related symptoms have been suggested to be associated with an altered pattern of endogenous melatonin. Melatonin is involved in the regulation of several physiological processes, including circadian rhythms, pain, mood, and oxidative as well as immunomodulatory balance. Preliminary clinical studies have propounded that the administration of different doses of melatonin to patients with FMS can reduce pain levels and ameliorate mood and sleep disturbances. Moreover, the total antioxidant capacity, 6-sulfatoxymelatonin and urinary cortisol levels, and other biological parameters improve after the ingestion of melatonin. Recent investigations have proposed a pathophysiological relationship between mitochondrial dysfunction, oxidative stress, and FMS by looking at certain proteins involved in mitochondrial homeostasis according to the etiopathogenesis of this syndrome. These improvements exert positive effects on the quality of life of FMS patients, suggesting that the use of melatonin as a coadjuvant may be a successful strategy for the management of this syndrome.
RESUMEN
Background: Alzheimer's disease (AD) accompanied by psychotic symptoms (PS) has a poor prognosis and may be associated with imbalances in key neural proteins such as alpha-synuclein (AS). Aim: The aim of the study was to evaluate the diagnostic validity of AS levels in the cerebrospinal fluid (CSF) as a predictor of the emergence of PS in patients with prodromal AD. Materials and methods: Patients with mild cognitive impairment were recruited between 2010 and 2018. Core AD biomarkers and AS levels were measured in CSF obtained during the prodromal phase of the illness. All patients who met the NIA-AA 2018 criteria for AD biomarkers received treatment with anticholinesterasic drugs. Follow-up evaluations were conducted to assess patients for the presence of psychosis using current criteria; the use of neuroleptic drugs was required for inclusion in the psychosis group. Several comparisons were made, taking into account the timing of the emergence of PS. Results: A total of 130 patients with prodromal AD were included in this study. Of these, 50 (38.4%) met the criteria for PS within an 8-year follow-up period. AS was found to be a valuable CSF biomarker to differentiate between the psychotic and non-psychotic groups in every comparison made, depending on the onset of PS. Using an AS level of 1,257 pg/mL as the cutoff, this predictor achieved at least 80% sensitivity. Conclusion: To our knowledge, this study represents the first time that a CSF biomarker has shown diagnostic validity for prediction of the emergence of PS in patients with prodromal AD.
RESUMEN
In Alzheimer's disease (AD), the reduction in acetylcholinesterase (AChE) enzymatic activity is not paralleled with changes in its protein levels, suggesting the presence of a considerable enzymatically inactive pool in the brain. In the present study, we validated previous findings, and, since inactive forms could result from post-translational modifications, we analyzed the glycosylation of AChE by lectin binding in brain samples from sporadic and familial AD (sAD and fAD). Most of the enzymatically active AChE was bound to lectins Canavalia ensiformis (Con A) and Lens culinaris agglutinin (LCA) that recognize terminal mannoses, whereas Western blot assays showed a very low percentage of AChE protein being recognized by the lectin. This indicates that active and inactive forms of AChE vary in their glycosylation pattern, particularly in the presence of terminal mannoses in active ones. Moreover, sAD subjects showed reduced binding to terminal mannoses compared to non-demented controls, while, for fAD patients that carry mutations in the PSEN1 gene, the binding was higher. The role of presenilin-1 (PS1) in modulating AChE glycosylation was then studied in a cellular model that overexpresses PS1 (CHO-PS1). In CHO-PS1 cells, binding to LCA indicates that AChE displays more terminal mannoses in oligosaccharides with a fucosylated core. Immunocytochemical assays also demonstrated increased presence of AChE in the trans-Golgi. Moreover, AChE enzymatic activity was higher in plasmatic membrane of CHO-PS1 cells. Thus, our results indicate that PS1 modulates trafficking and maturation of AChE in Golgi regions favoring the presence of active forms in the membrane.
Asunto(s)
Acetilcolinesterasa , Enfermedad de Alzheimer , Cricetinae , Animales , Humanos , Acetilcolinesterasa/metabolismo , Presenilina-1/genética , Presenilina-1/metabolismo , Enfermedad de Alzheimer/metabolismo , Lectinas/metabolismo , Encéfalo/metabolismo , Cricetulus , Presenilina-2/genética , MutaciónRESUMEN
Background: Alzheimer's disease (AD) is characterized by the presence of ß-amyloid plaques and neurofibrillary tangles, while Lewy body dementia (LBD) is characterized by α-synuclein (α-syn) inclusions. Some authors examine α-syn protein in the neurodegeneration process of AD and propose to consider cerebrospinal fluid (CSF) α-syn as a possible additional biomarker to the so-called "core" of AD. Objective: To determine whether there is a correlation between α-syn levels and "core" AD biomarkers in patients with mild cognitive impairment (MCI). Materials and methods: In total, 81 patients in the early stages of MCI were selected from the outpatient dementia consultation in Alicante General Hospital. Using a cross-sectional case-control design, patients were analyzed in four groups: stable MCI (MCIs; n = 25), MCI due to AD (MCI-AD; n = 32), MCI due to LBD (MCI-LBD; n = 24) and a control group of patients with acute or chronic headache (Ctrl; n = 18). Correlation between CSF protein levels in the different groups was assessed by the Rho Spearman test. Results: We found positive correlations between T-tau protein and α-syn (ρ = 0.418; p value < 0.05) and p-tau181p and α-syn (ρ = 0.571; p value < 0.05) exclusively in the MCI-AD group. Conclusion: The correlation found between α-syn and tau proteins in the first stages of AD support the involvement of α-syn in the pathogenesis of AD. This result may have clinical and diagnostic implications, as well as help to apply the new concept of "precision medicine" in patients with MCI.
Asunto(s)
Enfermedad de Alzheimer , Enfermedad por Cuerpos de Lewy , Enfermedad de Alzheimer/diagnóstico , Biomarcadores , Estudios Transversales , Humanos , Enfermedad por Cuerpos de Lewy/diagnóstico , alfa-SinucleínaRESUMEN
Studies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at different phases of the infection. Human plasma ACE2 species were characterized by immunoprecipitation and western blotting employing antibodies against the ectodomain and the C-terminal domain, using a recombinant human ACE2 protein as control. In addition, changes in the cleaved and full-length ACE2 species were also examined in serum samples derived from humanized K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2. ACE2 immunoreactivity was present in human plasma as several molecular mass species that probably comprise truncated (70 and 75 kDa) and full-length forms (95, 100, 130, and 170 kDa). COVID-19 patients in the acute phase of infection (n = 46) had significantly decreased levels of ACE2 full-length species, while a truncated 70-kDa form was marginally higher compared with non-disease controls (n = 26). Levels of ACE2 full-length species were in the normal range in patients after a recovery period with an interval of 58-70 days (n = 29), while the 70-kDa species decreased. Levels of the truncated ACE2 species served to discriminate between individuals infected by SARS-CoV-2 and those infected with influenza A virus (n = 17). In conclusion, specific plasma ACE2 species are altered in patients with COVID-19 and these changes normalize during the recovery phase. Alterations in ACE2 species following SARS-CoV-2 infection warrant further investigation regarding their potential usefulness as biomarkers for the disease process and to asses efficacy during vaccination.
Asunto(s)
Enzima Convertidora de Angiotensina 2/sangre , COVID-19/sangre , SARS-CoV-2 , Adulto , Anciano , Anciano de 80 o más Años , Enzima Convertidora de Angiotensina 2/líquido cefalorraquídeo , Enzima Convertidora de Angiotensina 2/química , Enzima Convertidora de Angiotensina 2/orina , Biomarcadores/sangre , Química Encefálica , Colon/química , Femenino , Humanos , Hígado/química , Masculino , Persona de Mediana Edad , Saliva/químicaRESUMEN
This study aims to genetically characterize a two-year-old patient suffering from multiple systemic abnormalities, including skeletal, nervous and developmental involvements and Leber congenital amaurosis (LCA). Genetic screening by next-generation sequencing identified two heterozygous pathogenic variants in nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) as the molecular cause of the disease: c.439+5G>T and c.299+526_*968dup.This splice variant has never been reported to date, whereas pathogenic duplication has recently been associated with cases displaying an autosomal recessive disorder that includes a severe form of spondylo-epiphyseal dysplasia, sensorineural hearing loss, intellectual disability and LCA (SHILCA), as well as some brain anomalies. Our patient presented clinical manifestations which correlated strongly with this reported syndrome. To further study the possible transcriptional alterations resulting from these mutations, mRNA expression assays were performed in the patient and her father. The obtained results detected aberrant alternative transcripts and unbalanced levels of expression, consistent with severe systemic involvement. Moreover, these analyses also detected a novel NMNAT1 isoform, which is variably expressed in healthy human tissues. Altogether, these findings represent new evidence of the correlation of NMNAT1 and SHILCA syndrome, and provide additional insights into the healthy and pathogenic expression of this gene.
Asunto(s)
Pérdida Auditiva Sensorineural/patología , Discapacidad Intelectual/patología , Amaurosis Congénita de Leber/patología , Nicotinamida-Nucleótido Adenililtransferasa/genética , Osteocondrodisplasias/patología , Preescolar , Femenino , Pérdida Auditiva Sensorineural/complicaciones , Pérdida Auditiva Sensorineural/genética , Heterocigoto , Humanos , Discapacidad Intelectual/complicaciones , Discapacidad Intelectual/genética , Amaurosis Congénita de Leber/complicaciones , Amaurosis Congénita de Leber/genética , Masculino , Mutación , Osteocondrodisplasias/complicaciones , Osteocondrodisplasias/genética , Linaje , Isoformas de ProteínasRESUMEN
In Alzheimer's disease (AD), the enzyme acetylcholinesterase (AChE) co-localizes with hyperphosphorylated tau (P-tau) within neurofibrillary tangles. Having demonstrated that AChE expression is increased in the transgenic mouse model of tau Tg-VLW, here we examined whether modulating phosphorylated tau levels by over-expressing wild-type human tau and glycogen synthase kinase-3ß (GSK3ß) influences AChE expression. In SH-SY5Y neuroblastoma cells expressing higher levels of P-tau, AChE activity and protein increased by (20% ± 2%) and (440% ± 150%), respectively. Western blots and qPCR assays showed that this increment mostly corresponded to the cholinergic ACHE-T variant, for which the protein and transcript levels increased ~60% and ~23%, respectively. Moreover, in SH-SY5Y cells differentiated into neurons by exposure to retinoic acid (10 µM), over-expression of GSK3ß and tau provokes an imbalance in cholinergic activity with a decrease in the neurotransmitter acetylcholine in the cell (45 ± 10%). Finally, we obtained cerebrospinal fluid (CSF) from AD patients enrolled on a clinical trial of tideglusib, an irreversible GSK3ß inhibitor. In CSF of patients that received a placebo, there was an increase in AChE activity (35 ± 16%) respect to basal levels, probably because of their treatment with AChE inhibitors. However, this increase was not observed in tideglusib-treated patients. Moreover, CSF levels of P-tau at the beginning measured by commercially ELISA kits correlated with AChE activity. In conclusion, this study shows that P-tau can modulate AChE expression and it suggests that AChE may possibly increase in the initial phases of AD.
Asunto(s)
Acetilcolinesterasa/biosíntesis , Enfermedad de Alzheimer/metabolismo , Regulación Enzimológica de la Expresión Génica , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Proteínas tau/metabolismo , Acetilcolinesterasa/genética , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/genética , Animales , Biomarcadores/líquido cefalorraquídeo , Biomarcadores/metabolismo , Células CHO , Línea Celular Tumoral , Células Cultivadas , Cricetinae , Cricetulus , Femenino , Glucógeno Sintasa Quinasa 3 beta/genética , Humanos , Masculino , Ratones , Ratones Endogámicos ICR , Persona de Mediana Edad , Fosforilación/fisiología , Embarazo , Xenopus , Proteínas tau/líquido cefalorraquídeo , Proteínas tau/genéticaRESUMEN
Previous studies have indicated the potential of cerebrospinal fluid (CSF) α-synuclein (α-syn) to be an additional biomarker for improving differential diagnosis of Alzheimer's disease (AD). We evaluated α-syn diagnostic performance across a well-characterized patient cohort with long-term follow-up. For this purpose, CSF α-syn levels were determined in 25 subjects diagnosed with stable mild cognitive impairment (stable MCI; n = 25), 27 MCI cases due to AD (MCI-AD; n = 32), 24 MCI cases due to Lewy body disease (MCI-LBD; n = 24) and control subjects (Ctrl; n = 18). CSF α-syn levels discriminate between the four groups. There were higher α-syn levels in MCI-AD patients and lower levels in MCI-LBD patients. The combination of α-syn and P-tau resulted in a specificity of 99% and a sensitivity of 97% for MCI-AD. MCI-AD patients with early psychotic symptoms (n = 9) displayed a trend towards a decrease in P-tau and α-syn compared to the MCI-AD patients without psychotic symptoms (n = 23). We conclude that adding CSF α-syn to central core AD biomarkers improves an early differential diagnosis of MCI-AD from other forms of MCI. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.
Asunto(s)
Enfermedad de Alzheimer/complicaciones , Biomarcadores/líquido cefalorraquídeo , Disfunción Cognitiva/diagnóstico , Disfunción Cognitiva/etiología , alfa-Sinucleína/líquido cefalorraquídeo , Anciano , Enfermedad de Alzheimer/líquido cefalorraquídeo , Disfunción Cognitiva/líquido cefalorraquídeo , Estudios Transversales , Diagnóstico Diferencial , Diagnóstico Precoz , Femenino , Humanos , Enfermedad por Cuerpos de Lewy/diagnóstico , Masculino , Persona de Mediana Edad , Proteínas tau/líquido cefalorraquídeoRESUMEN
OBJECTIVES: To know the effectiveness and safety of non-supervised breathing exercise regimen by promoting patients' self-management, and to investigate if non-supervised breathing exercise regimen shows similar benefits to supervised regimen in improving pain and fibromyalgia (FM) impact on daily life. MATERIAL AND METHODS: Fifty-one women with FM were assigned to: supervised breathing exercise regimen group, non-supervised breathing exercise regimen group, and control group. Pain thresholds tolerance on tender points and FM impact on daily life were evaluated. RESULTS: After 12-weeks of breathing exercises statistical differences were not found between supervised and non-supervised regimen. However, supervised regimen showed additional improvements in pain thresholds tolerance and in pain-FIQ subscale. CONCLUSION: Our results suggest that performing a non-supervised breathing exercise program could be as safe and effective as the supervised regimen. However, it was observed that there could be a tendency of supervised exercise regimen to show additional benefits in terms of pain.
Asunto(s)
Ejercicios Respiratorios/métodos , Fibromialgia/terapia , Adulto , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Dimensión del Dolor , Umbral del Dolor , Resultado del TratamientoRESUMEN
PURPOSE: To assess how the current practice of newborn screening (NBS) for homocystinurias compares with published recommendations. METHODS: Twenty-two of 32 NBS programmes from 18 countries screened for at least one form of homocystinuria. Centres provided pseudonymised NBS data from patients with cystathionine beta-synthase deficiency (CBSD, n = 19), methionine adenosyltransferase I/III deficiency (MATI/IIID, n = 28), combined remethylation disorder (cRMD, n = 56) and isolated remethylation disorder (iRMD), including methylenetetrahydrofolate reductase deficiency (MTHFRD) (n = 8). Markers and decision limits were converted to multiples of the median (MoM) to allow comparison between centres. RESULTS: NBS programmes, algorithms and decision limits varied considerably. Only nine centres used the recommended second-tier marker total homocysteine (tHcy). The median decision limits of all centres were ≥ 2.35 for high and ≤ 0.44 MoM for low methionine, ≥ 1.95 for high and ≤ 0.47 MoM for low methionine/phenylalanine, ≥ 2.54 for high propionylcarnitine and ≥ 2.78 MoM for propionylcarnitine/acetylcarnitine. These decision limits alone had a 100%, 100%, 86% and 84% sensitivity for the detection of CBSD, MATI/IIID, iRMD and cRMD, respectively, but failed to detect six individuals with cRMD. To enhance sensitivity and decrease second-tier testing costs, we further adapted these decision limits using the data of 15 000 healthy newborns. CONCLUSIONS: Due to the favorable outcome of early treated patients, NBS for homocystinurias is recommended. To improve NBS, decision limits should be revised considering the population median. Relevant markers should be combined; use of the postanalytical tools offered by the CLIR project (Collaborative Laboratory Integrated Reports, which considers, for example, birth weight and gestational age) is recommended. tHcy and methylmalonic acid should be implemented as second-tier markers.
Asunto(s)
Homocistinuria/diagnóstico , Acetilcarnitina/metabolismo , Errores Innatos del Metabolismo de los Aminoácidos/diagnóstico , Errores Innatos del Metabolismo de los Aminoácidos/metabolismo , Carnitina/análogos & derivados , Carnitina/metabolismo , Femenino , Glicina N-Metiltransferasa/deficiencia , Glicina N-Metiltransferasa/metabolismo , Homocisteína/metabolismo , Homocistinuria/metabolismo , Humanos , Recién Nacido , Masculino , Metionina/metabolismo , Metilenotetrahidrofolato Reductasa (NADPH2)/deficiencia , Metilenotetrahidrofolato Reductasa (NADPH2)/metabolismo , Ácido Metilmalónico/metabolismo , Espasticidad Muscular/diagnóstico , Espasticidad Muscular/metabolismo , Tamizaje Neonatal/métodos , Fenilalanina/metabolismo , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/metabolismoRESUMEN
Fundamento y objetivo: Comparar la evolución tras una descompensación aguda de los pacientes con insuficiencia cardiaca (ICA) con fracción de eyección del ventrículo izquierdo intermedia (ICFEi) respecto a los que la tienen deprimida (ICFEd) o conservada (ICFEc). Pacientes y método: Estudio observacional prospectivo, de inclusión consecutiva de pacientes diagnosticados de ICA en 41 servicios de urgencias. Se formaron 3 grupos: ICFEd<40%, ICFEi 40-49% e ICFEc≥50%. Se recogieron 38 variables independientes y se comparó la mortalidad por cualquier causa al año en el grupo de ICFEi, bruta y ajustada, respecto a los de ICFEd e ICFEc. Se estratificó este análisis según el destino del paciente tras la asistencia urgente. Resultados: Se incluyeron 3.958 pacientes: 580 ICFEi (14,6%), 929 ICFEd (23,5%) y 2.449 ICFEc (61,9%). La mortalidad global al año fue del 28,5%. La mortalidad bruta en la ICFEi fue similar a la ICFEc (HR 1,009; IC 95% 0,819-1,243; p=0,933) y menor que la ICFEd (HR 0,800; IC 95% 0,635-1,008; p=0,058), pero tras el ajuste por las características basales discordantes entre grupos, la mortalidad de la ICFEi no difirió de la ICFEc (HRa 1,025; IC 95% 0,825-1,275; p=0,821) ni de la ICFEd (HRa 0,924; IC 95% 0,720-1,186; p=0,535). El análisis estratificado según el destino del ingreso o alta directa desde Urgencias tampoco mostró diferencias significativas entre la ICFEi y los otros 2 grupos. Conclusión: La mortalidad a un año tras un episodio de ICA en pacientes con ICFEi no difiere de la de los pacientes con ICFEc o ICFEd, ni globalmente ni para ninguno de los principales destinos tras la asistencia en Urgencias
Background and objective: To compare the outcome of patients with acute heart failure (AHF) with a mid-range left ventricular ejection fraction (HFmrEF) with patients with a reduced (HFrEF) or preserved (HFpEF) left ventricular ejection fraction. Patients and method: A prospective observational study included patients diagnosed with AHF in 41 emergency departments. Patients were divided into 3 groups: HFrEF<40%, HFmrEF 40-49% and HFpEF≥50%. We collected 38 independent variables and the adjusted and crude all-cause mortality at one-year in the HFmrEF group was compared with that of the HFrEF and HFpEF groups. The analysis was stratified according to patient destination following ED care. Results: Three thousand nine hundred and fifty-eight patients were included: 580 HFmrEF (14.6%), 929 HFrEF (23.5%) and 2,449 HFpEF (61.9%). Global mortality at one year was 28.5%. The crude mortality of the HFmrEF group was similar to that of the HFpEF group (HR 1.009; 95% CI 0.819-1.243; P=.933) and lower than the HFrEF group (HR 0.800; 95% CI 0.635-1.008; P=.058), but after adjustment for discordant basal characteristics among groups, the mortality of the HFmrEF group did not differ from that of the HFpEF (HRa 1.025; 95% CI 0.825-1.275; P=.821) or HFrEF group (HRa 0.924; 95% CI 0.720-1.186; P=.535). Neither were significant differences found between the HFmrEF group and the other 2 groups in the analysis stratified according to admission or discharge direct from the emergency department. Conclusion: Mortality at one-year after an AHF episode in patients with HFmrEF does not differ from that of patients with HFpEF or HfrEF, either globally or based on the main destinations after emergency department care
Asunto(s)
Humanos , Femenino , Anciano , Anciano de 80 o más Años , Insuficiencia Cardíaca/mortalidad , Función Ventricular/fisiología , Hospitalización , Volumen Sistólico/fisiología , Estudio Observacional , Estudios ProspectivosRESUMEN
OBJECTIVE: During cardiology training, the cardiology fellow has to be trained in all things related to the indication, interpretation, and performing of nuclear cardiology studies using single photon emission computed tomography (SPECT). The aim of the present study was to analyse the relationship between the adequacy of indications of myocardial perfusion gated-SPECT and the years of experience since the completion of cardiology training. METHOD: A descriptive, retrospective analysis was performed on a single-centre register, in which the indications (adequate or inadequate use) were recorded according to myocardial perfusion gated-SPECT guidelines, prescribed by cardiologists of a university hospital. RESULTS: A total of 950 gated-SPECT tests were analysed according to the appropriate or inadequate indication. The sample of study was distributed in quartiles (years) since the cardiologist finished the residency. Cardiologists with less than 10 years of clinical experience reported a higher proportion of gated-SPECT tests compared to the more experienced cardiologists (87.6 vs. 9.3%, P<.001). After adjusting for age, gender, and cardiovascular risk factors, the multivariate analysis showed that, for each year of experience after completion of cardiology training, the probability of adequately indicating the test (OR: 1.33, 95% CI: 1.29-1.38, P<.001) was statistically significant. CONCLUSIONS: The professional experience of the clinical cardiologist is the most important factor to perform an appropriate indication of gated-SPECT myocardial perfusion.
Asunto(s)
Tomografía Computarizada por Emisión de Fotón Único Sincronizada Cardíaca/métodos , Cardiólogos/normas , Competencia Clínica , Imagen de Perfusión Miocárdica/métodos , Anciano , Cardiólogos/educación , Cardiología/educación , Femenino , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Guías de Práctica Clínica como Asunto , Estudios RetrospectivosRESUMEN
BACKGROUND AND OBJECTIVE: To compare the outcome of patients with acute heart failure (AHF) with a mid-range left ventricular ejection fraction (HFmrEF) with patients with a reduced (HFrEF) or preserved (HFpEF) left ventricular ejection fraction. PATIENTS AND METHOD: A prospective observational study included patients diagnosed with AHF in 41 emergency departments. Patients were divided into 3 groups: HFrEF<40%, HFmrEF 40-49% and HFpEF≥50%. We collected 38 independent variables and the adjusted and crude all-cause mortality at one-year in the HFmrEF group was compared with that of the HFrEF and HFpEF groups. The analysis was stratified according to patient destination following ED care. RESULTS: Three thousand nine hundred and fifty-eight patients were included: 580 HFmrEF (14.6%), 929 HFrEF (23.5%) and 2,449 HFpEF (61.9%). Global mortality at one year was 28.5%. The crude mortality of the HFmrEF group was similar to that of the HFpEF group (HR 1.009; 95% CI 0.819-1.243; P=.933) and lower than the HFrEF group (HR 0.800; 95% CI 0.635-1.008; P=.058), but after adjustment for discordant basal characteristics among groups, the mortality of the HFmrEF group did not differ from that of the HFpEF (HRa 1.025; 95% CI 0.825-1.275; P=.821) or HFrEF group (HRa 0.924; 95% CI 0.720-1.186; P=.535). Neither were significant differences found between the HFmrEF group and the other 2 groups in the analysis stratified according to admission or discharge direct from the emergency department. CONCLUSION: Mortality at one-year after an AHF episode in patients with HFmrEF does not differ from that of patients with HFpEF or HfrEF, either globally or based on the main destinations after emergency department care.
Asunto(s)
Insuficiencia Cardíaca/mortalidad , Insuficiencia Cardíaca/fisiopatología , Volumen Sistólico , Enfermedad Aguda , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Admisión del Paciente , Estudios ProspectivosRESUMEN
Resumen Objetivo: Durante el período de formación, el residente de cardiología ha de entrenarse en todo lo relacionado con la indicación, la interpretación y realización de imágenes en cardiología nuclear que usan la tomografía computarizada por emisión de fotón simple (SPECT). El objetivo del presente estudio fue analizar la relación existente entre la adecuación de las indicaciones del gated-SPECT de perfusión miocárdica y los años de experiencia desde la finalización de la residencia de cardiología. Método: Registro descriptivo, retrospectivo y unicéntrico, en el que se analizaron las indicaciones (uso adecuado e inadecuado), según las guías de la gated-SPECT de perfusión miocárdica, prescritas por cardiólogos de un hospital universitario. Resultados: Se analizaron un total de 950 pruebas de gated-SPECT de acuerdo a la indicación adecuada e inadecuada y se distribuyeron por cuartiles los años de finalización de la residencia del cardiólogo prescriptor. Los cardiólogos de menos de 10 años de experiencia clínica indican de forma inadecuada una mayor proporción de pruebas de gated-SPECT que los cardiólogos de mayor experiencia (87,6 vs. 9,3%: p < 0,001). Tras ajustar por edad, sexo y factores de riesgo cardiovascular, el análisis multivariante mostró que por cada año de experiencia tras finalizar la residencia de cardiología aumenta un 33% la probabilidad de indicar de forma adecuada la prueba (OR: 1,33; IC 95%: 1,29-1,38; p < 0,001). Conclusiones: La experiencia profesional del cardiólogo clínico es el factor más importante para realizar una indicación adecuada de la gated-SPECT de perfusión miocárdica.
Abstract Objective: During cardiology training, the cardiology fellow has to be trained in all things related to the indication, interpretation, and performing of nuclear cardiology studies using single photon emission computed tomography (SPECT). The aim of the present study was to analyse the relationship between the adequacy of indications of myocardial perfusion gated-SPECT and the years of experience since the completion of cardiology training. Method: A descriptive, retrospective analysis was performed on a single-centre register, in which the indications (adequate or inadequate use) were recorded according to myocardial perfusion gated-SPECT guidelines, prescribed by cardiologists of a university hospital. Results: A total of 950 gated-SPECT tests were analysed according to the appropriate or inade- quate indication. The sample of study was distributed in quartiles (years) since the cardiologist finished the residency. Cardiologists with less than 10 years of clinical experience reported a higher proportion of gated-SPECT tests compared to the more experienced cardiologists (87.6 vs. 9.3%, P < .001). After adjusting for age, gender, and cardiovascular risk factors, the multiva- riate analysis showed that, for each year of experience after completion of cardiology training, the probability of adequately indicating the test (OR: 1.33, 95% CI: 1.29-1.38, P < .001) was statistically significant. Conclusions: The professional experience of the clinical cardiologist is the most important factor to perform an appropriate indication of gated-SPECT myocardial perfusion.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Competencia Clínica , Tomografía Computarizada por Emisión de Fotón Único Sincronizada Cardíaca , Imagen de Perfusión Miocárdica/métodos , Cardiólogos/normas , Cardiología/educación , Análisis Multivariante , Estudios Retrospectivos , Guías de Práctica Clínica como Asunto , Cardiólogos/educación , Hospitales UniversitariosRESUMEN
Objetivo. Elaborar un listado de condiciones más allá de las condiciones médicas de la OMS que puedan ayudar en la toma de decisiones durante el proceso de asesoría anticonceptiva. Métodos. Estudio Delphi en el que 27 expertos contestaron a 24 preguntas planteadas por los coordinadores del estudio. Se requirió un nivel de consenso igual o superior al 50% del total de expertos consultados en cada una de las preguntas con respuesta de escala nominal formulada. Resultados. Tras el proceso Delphi se realizaron 20 recomendaciones sobre cuestiones relacionadas con el consejo anticonceptivo: condiciones médicas, época de la vida, estilo de vida, estado laboral, nivel académico, nivel económico, actividad sexual, métodos anticonceptivos y cumplimiento con el régimen anticonceptivo. Conclusiones. El consejo anticonceptivo debe de contemplar, además de las condiciones médicas, los aspectos relacionados con el estilo de vida de la mujer para mejorar la adherencia al método anticonceptivo más adecuado (AU)
Objective. To present a list of factors that go beyond the medical conditions established by the World Health Organization to assist decision-making during the process of contraceptive counseling. Methods. A Delphi study was carried out, in which 27 experts responded to 24 questions posed by the study coordinators. At least 50% agreement among the experts on a nominal scale was required in each of the questions. Results. After the Delphi process, 20 recommendations were made on issues related to contraceptive counseling: medical conditions, stage of life, lifestyle, employment status, educational level, economic status, sexual activity, contraceptive methods and contraceptive adherence. Conclusions. In addition to medical conditions, contraceptive counseling should include issues related to women's lifestyles in order to improve adherence to the most appropriate contraceptive method (AU)